114 research outputs found
ν΄λ©΄νκ΄κΈ°ν κ΄λ ¨ λμ μ¦ νμλ₯Ό λμμΌλ‘ ν μ½λ¬Όμ μΉλ£μ μ₯κΈ°μ μν
Dept. of Medicine/μμ¬Purpose: The study was conducted to assess the long-term outcome of antiepileptic drug (AED) treatment in drug-naοΌve patients with cavernous malformation related epilepsy (CRE)
Methods: This is a retrospective, single-center, long-term observational study. Study included patients presented to the epilepsy clinic between 2000 and 2011 with previously untreated seizures related to MRI-proven, cavernous malformation (CM). All patients were followed-up for at least two years. Previous history of surgical or AEDs treatment, lack of EEG examination, no or only a single previous seizure were exclusion criteria. Seizure outcome was assessed on annual basis and patients were divided into two groups according to the success (Group 1) or failure (Group 2) to achieve terminal 1-year seizure remission (1-year TSR). Drug resistant epilepsy (DRE) was defined as two or more seizures per year after trial of two appropriate AEDs. Patients who had only one seizure during the previous one year were assigned as βepilepsy with rare seizure (ERS)β.
Results: A total of 34 drug-naοΌve patients (male 20) were included to the study. Mean duration of follow up was 5.88 Β± 3.15 years. Pre-treatment baseline mean and median seizure frequencies were 4.93 Β± 12.63 and 0.85 (1.92) episodes per month, respectively. 1-year TSR was achieved in 22 of 34 (64.7%) patients, nine (26.5%) patients were diagnosed as DRE, and three (8.82%) patients were as ERS. 1-year TSR was achieved in 18 of 34 (52.9%) patients by the first drug regimen and in additional four (11.8%) patients by the second drug regimen. Among 16 patients who failed to achieve 1-year TSR by the first drug monotherapy, three patients were ERS and did not undergo second drug trial. None of nine patients who failed to first two drug regimens did achieve 1-year TSR. Univariate analysis of multiple clinical variables disclosed that the location of CM in the temporal lobe was the only prognostic factor predicting a poor seizure outcome (p = 0.012).
Conclusion: 1-year TSR was achieved in 64.7% of newly diagnosed patients with CRE in a long-term AEDs therapy. Failure to achieve seizure-freedom after adequate trials of two AEDs is strongly recommended as criteria for their referral to surgical treatment. However, for patients with temporal lobe CRE, a presurgical evaluation may be considered appropriate once they failed to an adequate trial of the first drug.ope
The Effect of Communication Network on Youth Political Participation - Focused on the Participation in 'the Children and Youth Association of Seoul' based on Collective Decision Making Process
νμλ
Όλ¬Έ (λ°μ¬)-- μμΈλνκ΅ λνμ : μ¬νκ΅μ‘κ³Ό, 2015. 2. λͺ¨κ²½ν, HeeMin Kim.μ§κΈκΉμ§ μ μΉμ°Έμ¬λ μ£Όλ‘ μ±μΈ μ€μ¬μ μ κ±° νΉμ μμ(protest)μ νμ μμΌ λ°λΌλ³΄λ μΈ‘λ©΄μ΄ κ°νλ€. νμ§λ§ μ κ±°λ μΌμ μ°λ Ή μ΄μμ΄ λμ΄μΌ κ°λ₯νκ³ μμ νΉμ μ§νλ λ°μ λΆμ β€λ°μ¬νμ μΈ μ±ν₯μ΄ κ°νκΈ° λλ¬Έμ μ²μλ
λμμ μ μΉμ°Έμ¬λ μ μΉκ΅μ‘μ λ°©μμΌλ‘μ μ κ·ΌνκΈ° μ΄λ €μ λ€.
κ·Έλμ μ²μλ
μ μΉμ°Έμ¬ νλμ λν νλ¬Έμ μ°¨μμ μ°κ΅¬λ€μ λ€μν λΆμΌμ κ±Έμ³ μ΄λ£¨μ΄μ Έ μλ€. λλΆλΆ μ²μλ
μ ν μ μΉμ°Έμ¬ νλμ λν λΆμ보λ€λ μ±μΈκΈ°μ μ μΉμ°Έμ¬ μμ¬μ μ΄μ μ λ§μΆ μ°κ΅¬λ‘ μ§νλμλ€. λν νλμ€μ¬μ μ μΉμ°Έμ¬ νλμ λν΄μ μΈκΈν λλ μ²μλ
μ°Έμ¬, μ¬νμ°Έμ¬ νΉμ μ μΉμ°Έμ¬λΌλ κ°λ
μΌλ‘ νΌμ©λλ κ²½μ°κ° λ§μλ€. μ΄λ μ μΉμ°Έμ¬μ κ°λ
μ μκ° μ±μΈμ μ€μ¬μΌλ‘ μ΄λ£¨μ΄μ§μΌλ‘μ λνλλ νμμ΄λΌ λ³Ό μ μλ€. νμ§λ§ μ²μλ
μ μ μΉμ°Έμ¬λ₯Ό μ±μΈκ³Ό λμΌν κΈ°μ€μ μ£λλ‘ λ
Όμνλ κ²μ μ μΉμ°Έμ¬μ λν μ€μ²μ ν¨μλ₯Ό μ μνκΈ°μ μ΄λ €μμ΄ λ°λ₯Έλ€. λ°λΌμ μ²μλ
μ μ μΉμ°Έμ¬μ λν μ¬μ μμ κ·Έμ λ°λ₯Έ νΉμ±μ μ΄ν΄λ³΄λ κ³Όμ μ νμνλ€.
λ³Έ μ°κ΅¬μμλ μ²μλ
μ μΉμ°Έμ¬λ₯Ό μ²μλ
μ΄ μ£Όμ²΄κ° λμ΄ μ§ννλ 곡곡μ μ±
μ΄λ νμ μ
무μμ μ²μλ
μ μν₯λ ₯μ νμ¬νλ λλΆλΆμ μ§ν©μ μ€μ² νμλ‘ μ μνλ€. μ΄μ λλΆμ΄ μ²μλ
μ μΉμ°Έμ¬μ νΉμ±μ΄ μ§ν©μ μΈ μμ¬κ²°μ μ μ€μ¬μΌλ‘ νλ€λ κ²μ κ³ λ €νμ¬ ν μ²μλ
μ μΉμ°Έμ¬ κ³Όμ μμ λ°μνλ μμ¬μν΅ μ°κ²°λ§μ μ΄μ μ λ§μΆκ³ μ νλ€.
μ΄μ λ³Έ μ°κ΅¬μ μ°κ΅¬ μ§λ¬Έμ λ€μκ³Ό κ°λ€.
1. μ§ν©μ μμ¬κ²°μ κ³Όμ μμ νμ±λ μμ¬μν΅ μ°κ²°λ§μ κ°μΈ
μμΈκ³Ό ꡬ쑰 μμΈμ μ²μλ
μ μΉμ°Έμ¬μ μ΄λ ν μν₯μ λ―ΈμΉλκ°?
2. μ§ν©μ μμ¬κ²°μ κ³Όμ μμ μμ¬μν΅ μ°κ²°λ§μ ννμ λ°λ¬κ³Όμ μ μ²μλ
μ μΉμ°Έμ¬μ μ΄λ ν μ°¨μ΄λ₯Ό κ°μ Έμ€λκ°?
μ΄λ¬ν μ°κ΅¬ μ§λ¬Έμ λ°λΌ μμ¬μν΅ μ°κ²°λ§μ μ€μ¬μΌλ‘ 100λͺ
μ μμΈμ μ΄λ¦°μ΄β€μ²μλ
μ°Έμ¬μμν μ 체μμμ λμμΌλ‘ νμ±λ λΆκ³Όλ³ μκ·λͺ¨ μ§λ¨μ λΆμ λμμΌλ‘ μΌμλ€. μ°κ΅¬ κ³Όμ μμλ μ‘°μ§ κ΅¬μ‘° λ΄μμ μ²μλ
μκ² μ΄λ ν κΈ°μ μ μλ¦¬κ° μ μ©λ λ μ²μλ
μ μΉμ°Έμ¬ νλμ ννλκ°μ λν΄ μ§μ€μ μΌλ‘ μ΄ν΄λ³΄μλ€.
μ΄λ₯Ό μν΄ λμΌν μ«μμ μκ·λͺ¨ μ§λ¨ λ΄μμ λ°μνλ μ‘°μ§ λ΄ μμ¬μν΅ μ°κ²°λ§μ μμλ₯Ό ν λλ‘ μ²μλ
μ μΉμ°Έμ¬λ₯Ό μ λ°νλ μμΈμ μ§μ€μ μΌλ‘ λ€λ£¨μλ€. νΉν, ꡬ쑰 λ΄μμ λ°μνλ μμ¬μν΅ μ°κ²°λ§μ λ°λ₯Έ κ°μΈ λ° κ΅¬μ‘° μμΈμ μ°¨μ΄μ κ·Όκ±°ν μ νλ³ νΉμ±μ μ°κ²°λ§ λΆμμ μ΄μ©ν΄ μ€μμ±κ³Ό μ§μνλ₯ κ·Έλνλͺ¨ν(ERGM)μ λ°λ₯Έ νΉμ ꡬ쑰 μ νμ λν΄ μ΄ν΄λ³΄μλ€. κ·Έ λ€μ, ꡬ쑰 μμΈμ΄ κ°μΈμ νλμ μ΄λ ν μν₯μ λ―ΈμΉλκ°μ λν΄μ λ€μΈ΅ λΆμμ μννμ¬ μ²μλ
μ μΉμ°Έμ¬μ κ°μΈμμΈκ³Ό ꡬ쑰μμΈμ΄ λ―ΈμΉλ μν₯μ λν΄ μμ보μλ€.
λ³Έ μ°κ΅¬μ λμμΈ μμΈμ μ΄λ¦°μ΄β€μ²μλ
μ°Έμ¬μμνμ κ²½μ°, λ€μν λ°°κ²½μ μ²μλ
λ€μ΄ νλμ 맀κ°λ‘ μ²μ λ§λμ μ§νμ νκΈ° λλ¬Έμ μ€μ νμμ μ°Έμ¬νλ μμλ€μ μμ¬μν΅ μ°κ²°λ§μ΄ κ° λΆκ³Όλ§λ€ μ°κ²°λ§ μμΈλ³ μ°¨μ΄κ° λ°μνμλ€. μ΄μ κ°μ μ°¨λ³μ νΉμ±μ μ§λ κ΅¬μ‘°κ° λνλλ κ·Όκ±°λ‘λ λΆκ³Ό λ΄μμ νν΄μ§λ μ 보μ λ¬ λ° μ견μλ ΄μ ν λλ‘ ν ν λ‘ κ³Όμ μ μμ΄ κ°μΈμ νΉμ±λ μν₯μ λ―ΈμΉμ§λ§ νμλ₯Ό μ£Όλνλ λΆκ³Όμ₯κ³Ό λΆλΆκ³Όμ₯μ 리λμκ³Ό μμλΆκ³Ό μμλ€κ³Όμ μμ¬μν΅ μ°κ²°λ§μ λ°λ₯Έ νΉμ±μ΄ μ°κ²°λ§ ꡬ쑰μ λ§μ μν₯μ λ―ΈμΉλ κ²μ μ μ μμλ€. μ°κ΅¬ κ²°κ³Όλ λ€μκ³Ό κ°λ€.
첫째, μ²μλ
μ°Έμ¬νλ κ³Όμ μμ κ°μΈ μμ€κ³Ό ꡬ쑰 μμ€ μμΈ λͺ¨λ μ²μλ
μ μΉμ°Έμ¬μ μν₯μ λ―ΈμΉλ κ²μΌλ‘ λνλ¬λ€.
λμ§Έ, μ₯κΈ°μ μΌλ‘ μ§μμ μΈ νλμ μꡬνλ μ§ν©μ μΈ μμ¬κ²°μ νλ‘κ·Έλ¨μ κ²½μ°, μμ¬μν΅ μ°κ²°λ§ λ³μκ° λͺ¨λ μ μλ―Έν κ²°κ³Όλ₯Ό λνλλ€. μ΄λ μ²μλ
μ°Έμ¬λ₯Ό λ€λ£¬ μ νμ°κ΅¬λ€κ³Όλ κ°μ₯ ν° μ°¨λ³μ μΈ νΉμ±μΌλ‘, μμ¬μν΅ μ°κ²°λ§μ΄ μ²μλ
μ μΉμ°Έμ¬μ λ―ΈμΉλ μν₯λ ₯μ μ€μ¦μ μΌλ‘ λΆμνμ¬ μ²μλ
λ€μ μ μΉμ°Έμ¬μ λν μ΄ν΄λ₯Ό νμ₯νκ³ μ¬νμμΌ°λ€λ μ μμ μμλ₯Ό κ°μ§λ€.
μ
μ§Έ, μμ¬μν΅ μ°κ²°λ§μμ μ€μμ±(centrality) ν¨κ³Όκ° λλ ·νκ² λνλ¬λ€. μ€μμ±μ μ°κ²°μ λ μ€μμ±, μΈμ μ€μμ±, λ§€κ° μ€μμ±μΌλ‘ ꡬλΆνμ¬ μ΄ν΄λ³Έ κ²°κ³Ό, λΆκ³Ό μ‘°μ§μ λ°λΌμ μμ¬μν΅ ν¨ν΄μ΄λ ννκ° λ€λ₯΄κ² λνλ¬λ€. μ΄λ₯Ό ν΅ν΄ κ° λΆκ³Όμ ꡬ쑰μ νΉμ±μ΄ κ°μΈνλμ μν₯μ λ―ΈμΉλ€λ κ²μ μ μ μμλ€. μ΄λ μ²μλ
μ μΉμ°Έμ¬κ° μ§ν©μ μΈ μ‘°μ§ νλ λ΄μμμ νμΈκ³Όμ κ΄κ³μ μν₯μ λ°λ κ²μ μμ¬νλ€.
λ·μ§Έ, ꡬ쑰 μμ€μμλ μ§μνλ₯ κ·Έλνλͺ¨ν(ERGM)μ μ΄μ©νμ¬ μ°κ²°λ§ ꡬ쑰 μμ€μμ νμμ κ°μ μνΈμμ©μ±, μ 보μ λ¬ κ³Όμ μμ μΌμ΄λλ λΉλμΉμ±, μ‘°μ§ λ΄μμ μΉκ΅¬μ μΉκ΅¬ κ°μ μ°κ²°μ΄ λ°μνλ κ²¬κ³ μ± νΉμ μ΄νμ±, κ·Έλ¦¬κ³ μΈ λͺ
μ νμμκ° νλμ μ°κ²°μ λ§Ίκ³ μλ μμ μ±μ ννλ‘ μ€μ μμ¬μν΅ μ°κ²°λ§μ΄ νμ±λ νλ₯ μ ν΅ν΄ μ‘°μ§λ³ μμ¬μν΅ μ°κ²°λ§μ μ νμ λ³Ό μ μμλ€. μ΄λ₯Ό ν΅ν΄ μ‘°μ§μ λ°λ₯Έ μ°κ²°λ§μ κ΅¬μ‘°κ° μ΄λ€ λ°©μμΌλ‘ 곡μ§ν(co-evolution) λλκ°μ λν μμΈ‘μ΄ κ°λ₯νλ€.
λμΌλ‘, κ°μΈ μμ€μ ν΅μ νκ³ κ΅¬μ‘° μμ€ λ³μΈμ ν¬ν¨νμ λ ꡬ쑰 μμ€ λ³μΈμ΄ μ²μλ
μ μΉμ°Έμ¬μ λ―ΈμΉλ μν₯μ μ μλ―Ένκ² λνλ¬λ€. μ΄λ μ§ν©ννμ μμ¬κ²°μ κ³Όμ μ ν¬ν¨νλ μ²μλ
μ°Έμ¬ νλ‘κ·Έλ¨μ μμ΄ κ°μΈ λ¨μλ₯Ό κΈ°μ΄λ‘ νλ κ΅μ‘ νλ λΏ μλλΌ μ‘°μ§ λ¨μμμ λ°μνλ ꡬμ±μκ°μ μ°κ²°λ§ μμΈμ λμμ κ³ λ €ν΄μΌ νλ€λ κ²μ μλ―Ένλ€.
κ·Έ λ°μ μμ¬μν΅ μ°κ²°λ§μμ λνλλ νΉμ§μΌλ‘λ λΆκ³Όμ₯μ 리λμ νν, λΆκ³Ό λ΄ κ·μΉ λ° λ³΄μκ³Ό μ²λ² κ·μ , νλΆ μ‘°μ§μ ν¬ν¨ν μμ μ‘°μ§μ μμμ μμ λΆκ³Ό μ‘°μ§μλ€μ μ°λ ΉνΈμ°¨μ λ°λΌμ λΆκ³Ό μ‘°μ§ κ° μ²μλ
μ μΉμ°Έμ¬μ μ°¨μ΄λ₯Ό 보μλ€. λλΆμ΄ λΆκ³Ό μ‘°μ§μκ°μ μ λ’°λμ μ견 μΌμΉλ λν μ²μλ
μ μΉμ°Έμ¬μ μν₯μ λ―Έμ³€λ€.
μ΄μ κ°μ΄ μ²μλ
λ€μ΄ μλ°μ μΌλ‘ μ μΉμ°Έμ¬λ₯Ό νλ κ³Όμ μμ λ°μνλ κ°μΈμ νλ λ³νμ λ°λ₯Έ μμ¬μν΅ μ°κ²°λ§ λΆμμ κ΅μ‘ νμ₯μ μ€μ²μ μΈ ν¨μλ₯Ό μ κ³΅ν΄ μ€ μ μμ κ²μ΄λ€. μ¦, μ§ν©μ μΈ μμ¬κ²°μ μ μν μ‘°μ§ ννμ μ μΉμ°Έμ¬ νλ λΆμμμ κ°μΈ νΉμ± λΏ μλλΌ κ΅¬μ‘° ννμ κ΄μ¬μ κ°λ κ²μ μ‘°μ§ νλμμμ νλ ₯μ κ°νν λΏ μλλΌ λ³΄λ€ ν¨κ³Όμ μΈ μ μΉ κ΅μ‘ λ°©μμ μμ¬μ μ μ 곡νλ€.β
. μ λ‘ 1
1. λ¬Έμ μ κΈ° 1
2. μ°κ΅¬λ¬Έμ 3
3. μ°κ΅¬μ μμ 6
4. μ°κ΅¬μ μ£Όμκ°λ
10
β
‘. μ΄λ‘ μ λ°°κ²½ 15
1. μ²μλ
μ μΉμ°Έμ¬μ μλ―Έμ νν© 15
1) μ²μλ
μ°Έμ¬μ μ²μλ
μ μΉμ°Έμ¬ 16
2) μ²μλ
μ μΉμ°Έμ¬μ μ μΉκ΅μ‘ 28
3) μ²μλ
μ μΉμ°Έμ¬ νλμ νν©κ³Ό νΉμ§ 35
2. μ²μλ
μ μΉμ°Έμ¬μμμ μ§ν©μ μμ¬κ²°μ 46
1) μ§ν©μ μμ¬κ²°μ μ μλ―Έ 46
2) μ§ν©μ μμ¬κ²°μ μ νΉμ§ 49
3. μ²μλ
μ μΉμ°Έμ¬μ μμ¬μν΅ μ°κ²°λ§ 56
1) μμ¬μν΅ μ°κ²°λ§μ μλ―Έ 57
2) μμ¬μν΅ μ°κ²°λ§μ μν 70
3) μ²μλ
μ μΉμ°Έμ¬μμ λνλλ μμ¬μν΅ μ°κ²°λ§ 73
4. μ νμ°κ΅¬ κ°κ΄ 76
β
’. μ°κ΅¬ μ€κ³ 82
1. μ°κ΅¬ μ§λ¬Έ 82
2. μ°κ΅¬ λ³μΈ 83
3. μ°κ΅¬ λ°©λ² 85
β
£. μ°κ΅¬ κ²°κ³Ό 109
1. μ²μλ
μ μΉμ°Έμ¬μ μν₯μ λ―ΈμΉλ μμΈ 109
2. μκ° νλ¦μ λ°λ₯Έ μμ¬μν΅ μ°κ²°λ§μ μ€μμ± λΆμ 114
1) 2μ°¨ νμ μ λΆκ³Όλ³ νκ· μ€μμ± 115
2) 16μ°¨ νμ μ λΆκ³Όλ³ νκ· μ€μμ± 128
3) 2μ°¨ λ° 16μ°¨ νμ μ λ°μν μμ¬μν΅ μ°κ²°λ§ λΉκ΅ 141
3. μ§μνλ₯ κ·Έλνλͺ¨ν(ERGM)μ νμ©ν μ‘°μ§ μ νμ
λ°λ₯Έ μμ¬μν΅ κ΅¬μ‘° λΆμ 152
1) AλΆκ³Όμ ꡬ쑰 μ ν νΉμ± 153
2) BλΆκ³Όμ ꡬ쑰 μ ν νΉμ± 154
3) CλΆκ³Όμ ꡬ쑰 μ ν νΉμ± 155
4) DλΆκ³Όμ ꡬ쑰 μ ν νΉμ± 156
5) EλΆκ³Όμ ꡬ쑰 μ ν νΉμ± 156
4. κ°μΈ λ° κ΅¬μ‘° μμΈμ΄ μ²μλ
μ μΉμ°Έμ¬μ λ―ΈμΉλ μν₯ 158
1) κΈ°λ³Έ λͺ¨ν λΆμ 160
2) κ°μΈ λ° κ΅¬μ‘° μμΈμ΄ μ²μλ
μ μΉμ°Έμ¬μ λ―ΈμΉλ μν₯ λΆμ 162
β
€. κ²° λ‘ 169
μ°Έ κ³ λ¬Έ ν 181
λΆ λ‘ 189
Abstract 209Docto
The Effect of Temperament on Neurocognitive Function in the Patients with Obsessive-Compulsive Disorder
νμλ
Όλ¬Έ (μμ¬)-- μμΈλνκ΅ λνμ : λμΈμ§κ³Όνκ³Ό(λμΈμ§κ³Όνμ 곡):, 2012. 8. κΆμ€μ.Background: Converging evidence revealed impaired cognitive function and distinct temperament pattern in obsessive-compulsive disorder (OCD). However, little is known about the relation between cognitive deficit and temperament in OCD. This study was aimed to investigate how temperament influences cognitive dysfunction in OCD.
Methods: The participants included 103 patients with OCD and 63 healthy controls. Cognitive functions were measured by the Trail Making Test (TMT), letter fluency, category fluency, and the Wisconsin Card Sorting Test (WCST). Temperament was assessed by Cloningers Temperament and Character Inventory (TCI).
Results: OCD patients showed poor performance in neuropsychological tests related to psychomotor speed, verbal fluency and set-shifting abilities compared to the healthy controls. Regarding temperaments, the OCD patients showed significantly lower novelty seeking and reward dependence and higher harm avoidance than the healthy controls. Temperament pattern affected impaired neurocognitive functions after controlling symptom severity in the OCD patients. And reward dependence partially mediated group differences between patients and controls in psychomotor speed and verbal fluency performances.
Conclusions: Cognitive impairment was influenced by temperament in the OCD patients regardless of their symptom severity. The present findings suggest that deficits of cognitive functions may be partially explained by temperamental traits of OCD patients.Abstract β
°
Contents β
³
List of tables and List of figures β
΄
Introduction 1
Methods 7
Results 12
Discussion 15
References 21
Tables 32
Figures 35
κ΅λ¬Έμ΄λ‘ 36Maste
Perceptions of Anticoagulation Therapy and Medication Adherence among Patients taking Warfarin
Purpose: This study was conducted to measure medication adherence and perceptions of anticoagulation therapy and its relationship to patients taking warfarin. Methods: In a cross-sectional survey, 150 patients taking warfarin who had visited an outpatient clinic of a cardiovascular center in Seoul were included as research subjects. Medication adherence was measured using a visual analogue rating scale (VAS). Barriers and attitudes toward adherence, and oral anticoagulation knowledge, were measured using a structured questionnaire. Participantsβ medical records also were reviewed to identify clinical characteristics. Results: About one third of the participants (30.7%) reported medication adherence as 100%. The major barriers to adherence were identified as βForgetting the time of medicationβ and βNot carrying their medicationββ. Overall attitudes toward medication adherence were high, but oral anticoagulation therapy knowledge was low. To determine the relationship of medication adherence and perceptions of anticoagulation therapy, participants were stratified into three groups, based on their medication adherence levels (high adherence, moderate adherence, low adherence). Participants in the high adherent group more likely to be older (OR: 1.04, 95% CI: 1.005-1.071) and to have positive attitudes toward medication adherence (OR: 1.12, 95% CI:1.013-1.229) compared to the other two groups. Conclusion: The results show that age and attitude exerts significant influence on medication adherence in patients taking warfarin.ope
A Strategic Plan of Urban Farmingβ§Garden Expo for the Vacant land in Janghang, Seochun-gun, Chungcheongnam-do
νμλ
Όλ¬Έ (μμ¬)-- μμΈλνκ΅ νκ²½λνμ : νκ²½μ‘°κ²½νκ³Ό, 2013. 8. μ±μ’
μ.μ ν΄μ§λ₯Ό νμ©ν λμλμ
Β·μ μλ°λν μ λ΅κ³ν
-μΆ©μ²λ¨λ μμ²κ΅° μ₯νμμ λμμΌλ‘-
μΆ©μ²λ¨λ μμ²κ΅° μ₯νμ 1930λ
λλΆν° 1980λ
λ νλ°κΉμ§ νκ΅μ κ²½μ
λ°μ μ μ€μν μν μ ν μ£Όμ λμμμΌλ, μλμ λ³νμ λ°λ₯Έ μ°μ
ꡬ쑰μ
λ³νλ‘ κ²½μ Β·μ¬νΒ·νκ²½Β·λ¬Έν λ± λμμ λ°μ μ ν΄κ° λνλ λμμ΄λ€. μ΄
λ¬ν μλμ λ³ν μμμ μ₯νμ μ§μμ¬νμ±νλ₯Ό μν λ°©μμΌλ‘ μ ν΄μ§λ₯Ό
νμ©ν λμλμ
Β·μ μλ°λν κ°λ
μ λμ
νκ³ μ νλ€.
μ μλ°λνμ μμ΄λ μ€μ λ° μ§λ°©μμΉλ¨μ²΄μ νκ²½λ¬Ένμ¬μ
μΌλ‘ μΆλ°ν
λ€κ³ λ³Ό μ μλ€. κ·Έλ¬λ μ΅κ·Ό λ
μΌμ λΉλ‘―ν μ¬λ¬ μ λ½κ΅κ° λ±μμ κ°μ΅λ
μ μλ°λνλ κ·Έ μ±κ²©μ΄ μΌνμ±μ λ¬Έννμ¬μ κ·ΈμΉλ κ²μ΄ μλλΌ, κ³ν μ΄
κΈ° λ¨κ³λΆν° νκ²½Β·κ²½μ Β·λ¬Έν λ±μ κ³ λ €ν λμκ°λ°(μ¬μ)μ ν μλ¨μΌλ‘
μ¨ κ·Έ ν¨κ³Όκ° μ¬μ‘°λͺ
λ°κ³ μλ€. λ°λΌμ μ₯νμ μ§μμ¬μμ λμμΌλ‘ λμ
λμ
Β·μ μλ°λνλ₯Ό μ μνλ€.
λ¨Όμ λμλμ
Β·μ μλ°λνλ κΈ°μ‘΄ μ μλ°λνμ μΌνμ±κ³Ό μ§μκ³Όμ μ°
κ³ λΆμ‘±μ΄λΌλ νκ³λ₯Ό 극볡ν λ°μ μ μΈ λμμΌλ‘μ¨ νμ¬ μ₯νμ μ ν΄μ§μμ
μ£Όλ―Όλ€μ μν΄ λ°μνκ³ μλ λμν
λ°μ μ μλ°λνμ κ²°ν©ν μλ‘μ΄ μ μ
λ¬Έν μ΄λ²€νΈμ΄λ€. λ°λΌμ λμλμ
Β·μ μλ°λν κ°μ΅λ₯Ό ν΅ν μ¬νμ±νλ₯Ό μ
ν΄ μ§μμ νν©, μμ¬μμ, μνλ¬Έν μμμ λ°κ΅΄κ³Ό νμ©μ μ€μ μ λμμΌ
λ©°, λ€μκ³Ό κ°μ λ΄μ©μ λμΆνμλ€.
첫째, νμ¬ μ₯νμμ λ°μλ μ ν΄μ§ μ€ νμ¬μ₯μΌλ‘ νμ© κ°λ₯ν μ ν΄μ§
μ λΆλ₯μ κ³νμ μ₯νμ 물리μ μννκ²½μ κ°μ νκ³ , μ§μμ κ°μΉλ₯Ό ν₯μ
μν€λ μ£Όμν 곡κ°μ μμμ΄λ€. λμ§Έ, μ₯ν μκ°μ§ κ³³κ³³μ μ°μ¬ν κ·Όλμ°μ
λμμ μμ¬μ μμμΈ κ΅¬ μ₯νμμ¬ λ° λΆμ§, μ₯νν, μ°½κ³ , κ·Όλ건μΆλ¬Ό λ±μ΄
μ‘΄μ¬νλ©°, μ΄λ μ§μμμ ν¨κ» 보쑴νκ³ κ΄λ¦¬ν΄λκ°μΌ νλ μμμΈ λμμ
μ₯νλ§μ μ°¨λ³νλ μ μλ°λνλ₯Ό μν νμμ μ΄λ€. μ
μ§Έ, μ₯ν μ£Όλ―Όμ νκ²½
μ μ¬κ±΄κ³Ό μνμ κΈ°λ°μΌλ‘ νμ±λ ν
λ°, μ μΈ΅μ£Όκ±°μ§μ 골λͺ©κΈΈ κ²½κ΄μ μ§μ
μ λ
νΉν μνμμ λλ¬λ΄λ μμμΌλ‘ μ§μμ νκ²½μ κ°μ νλ λμμ μ
λ―Όμ°Έμ¬μ μν λμμ μλ¬Έν λ° κ³΅κ³΅νκ²½μ λ₯λμ μΌλ‘ μ‘°μ±νκ³ κ΄λ¦¬νλ
λͺ¨λΈλ‘ λ°μ κ°λ₯ν μμμ΄λ€.
μμ κ°μ μ₯νμ λμμ§ μμλΆμ λ° κ°λ₯μ±μ ν΅ν΄ μ₯ν λμλμ
Β·
μ μλ°λνμ λΉμ , λͺ©ν, μ λ΅μ μ립νμλ€. μ₯νμ μ ν΄μ§λ₯Ό νμ©ν λμ
λμ
Β·μ μλ°λνλ₯Ό ν΅ν΄ λ
Ήμλ¬Ένμ λμμ λΉμ μ μ μνμμΌλ©° λͺ©νλ
λ€μκ³Ό κ°λ€.
첫째, νμ¬ μ₯νμμ μ§μμ¬νμ±νλ₯Ό μν΄ μνλκ³ μλ μ¬μ
λ€μ΄ ν
μ¬ κ°λ³λ¨μ μ¬μ
μ λ¨Έλ¬Όλ¬ μλ νκ³λ₯Ό 극볡νκΈ° μν΄ λμλμ
Β·μ μλ°λ
νλΌλ 곡ν΅λ λΉμ κ³Ό λͺ©ν μ μλ‘ κ° κ°λ³μ¬μ
λμμ§λ€μ λ°λν νμ¬ μ€
μμ€ λ° νμ¬κ³΅κ°μΌλ‘ νμ©νκΈ° μν ν΅ν©μ κ³νμ μ μνλ€. λμ§Έ, κ·Όλλ
μμΈ μ₯νμ΄ κ°μ§ μμμ λ°κ΅΄ λ° νμ©μ ν΅ν΄ κ° μμμ κ°μΉλ₯Ό λ°ννλ€.
μ
μ§Έ, μ§μμ£Όλ―Όμ μ°Έμ¬λ₯Ό ν΅ν΄ μ§μκ°λ₯μ±μ ν보νκ³ μ μ§μ μΈ μ§μμ¬νμ±
νλ₯Ό λλͺ¨νλ€.
μ΄μ κ°μ λΉμ κ³Ό λͺ©νλ₯Ό ν΅ν΄ λμλμ
Β·μ μλ°λνμ νμν μ λ΅κ³
νμ λμμ§, νλ‘κ·Έλ¨, 주체λ³, μκ°μ λ°λ₯Έ κ³νμΌλ‘ λλμ΄ νμ¬ κ°μ΅λ₯Ό
μν μ λ΅μ κ³νμ μ μνμλ€. μ΄μ κ°μ μ λ΅κ³νμ ν΅ν΄ μ ν΄μ§λ₯Ό νμ©
ν λμλμ
Β·μ μλ°λνμ λ€μν μμ΄λμ΄μ λν κ²ν μ λλΆμ΄ λ―Έλλ³
νμ μ μ°ν κ³νμμ μ μν¨μΌλ‘μ¨ λΆνμ€μ λν κ°λ₯ν κ³νμ μ μνκ³
μ νμλ€.1μ₯ μλ‘ 1
1μ . μ°κ΅¬μ λ°°κ²½ λ° λͺ©μ 1
1. μ°κ΅¬μ λ°°κ²½ 1
2. μ°κ΅¬μ λͺ©μ 2
2μ . μ°κ΅¬μ λ²μ 3
1. λ΄μ©μ λ²μ 3
2. 곡κ°μ λ²μ 3
3. μ°κ΅¬μ λ°©λ² λ° νλ¦ 4
μ 2μ₯ μ΄λ‘ μ κ³ μ°° 7
1μ . μ ν΄κ³΅κ°μ λ°μκ³Ό νμ©μ λν μ΄ν΄ 7
1. μ ν΄κ³΅κ°μ κ°λ
7
2. μ ν΄μ§ νμ©μ μ€μμ± 8
2μ . νλλμμ¬μμ μλ‘μ΄ μ΄λ§€μ λ‘μ λμλμ
κ³Ό μ μλ°λν10
1. νλλμμμ λμλμ
μ λν μ΄ν΄ 10
2. νλ μ μλ°λνμ μ΄ν΄ λ° μΆκ΅¬ν΄μΌν λ°©ν₯ 15
3μ , μ ν΄κ³΅κ°μ νμ©ν λμλμ
Β·μ μλ°λν μ μ©μ μν κ°λ
μ 립 21
1. λμλμ
Β·μ μλ°λνμ κ°λ
21
2. λμλμ
Β·μ μλ°λνμ κ³νμ ν μ 립 22
μ 3μ₯ μ₯ν λμλμ
Β·μ μλ°λν κ°μ΅λ₯Ό μν 쑰건ν΄μ 26
1μ . λμμ§ κ°μ 26
1. μ₯νμ μμ¬ 26
2. μμ°νκ²½λΆμ 27
3. μΈλ¬Έ μ¬ννκ²½λΆμ 28
2μ . κ³νμ¬κ±΄λΆμ 30
1. κ΄μνκ²½λΆμ 30
2. κ΄λ ¨κ³ν 31
3. μμ 33
3μ . μ ν΄μ§ νν© 38
1. μκ°μ§μ μμΉν μκ·λͺ¨ μ ν΄μ§ 38
2. λκ·λͺ¨ μ ν΄μ§ 40
4μ . λμμ§ μ’
ν©λΆμ λ° κ³Όμ 44
μ 4μ₯ μ₯ν μ ν΄μ§λ₯Ό νμ©ν λμλμ
Β·μ μλ°λν μ λ΅κ΅¬μ 50
1μ . μ₯νμ μ ν΄κ³΅κ°μ νμ©ν λμλμ
Β·μ μλ°λν κ°λ
52
1. λμλμ
Β·μ μλ°λνμ μν λ° κΈ°λ₯ 52
2. λμλμ
Β·μ μλ°λνμ κ°λ
53
2μ . μ₯νμ μ ν΄μ§ νμ©ν λμλμ
Β·μ μλ°λν λΉμ λ° λͺ©ν 55
1. μ₯ν λμλμ
Β·μ μλ°λνμ λΉμ 55
2. μ₯ν λμλμ
Β·μ μλ°λν λͺ©ν 55
3μ . μ₯ν μ ν΄μ§ νμ©ν λμλμ
Β·μ μλ°λν μ λ΅ κ΅¬μ 59
1. μ₯ν λμλμ
Β·μ μλ°λν κ°μ΅λ₯Ό μν λμμ§ μ μ 60
2. μ₯ν λμλμ
Β·μ μλ°λν νλ‘κ·Έλ¨ κ΅¬μ 64
3. μ₯ν λμλμ
Β·μ μλ°λν μ£Όμ²΄λ³ μ°Έμ¬ μ λ΅κ΅¬μ 66
4. λμλμ
Β·μ μλ°λνμ μκ°μ μ λ΅ κ΅¬μ 69
μ 5μ₯ μ₯ν μ ν΄μ§λ₯Ό νμ©ν λμλμ
Β·μ μλ°λν μ λ΅κ³ν 74
1μ . λμμ§λ³ κ³ν 75
1. μ£Όμ κ±°μ μμ€ λ° κ³΅κ°λ³ νμ©κ³ν 75
2. κ·Όλ건μΆλ¬Ό νμ©κ³ν 80
3. μ ν΄μ§ νμ©κ³ν 81
4. κ°μΈμμ ν
λ° νμ©κ³ν 82
2μ . μ₯ν λμλμ
Β·μ μλ°λν νλ‘κ·Έλ¨ κ³ν 83
1. λμλμ
Β·μ μ μ μ νλ‘κ·Έλ¨ 83
2. μννλ‘κ·Έλ¨ 86
3. λ¬Ένμμ νλ‘κ·Έλ¨ 87
3μ . μ₯ν λμλμ
Β·μ μλ°λν μ£Όμ²΄λ³ μ°Έμ¬κ³ν 90
1. μμ 주체μ λ°λ₯Έ κ³΅κ° νμ© 90
2. μ£Όμ²΄λ³ νλ μ°Έμ¬ 91
4μ . μκ°μ λ°λ₯Έ μ₯ν λμλμ
Β·μ μλ°λν μΆμ§ μ λ΅ 93
1. μμ€ λ° κ³΅κ°μ μ‘΄μΉ 93
2. λ¨κΈ°μ λ³ν 94
3. μ₯κΈ°μ λ³ν 95
5μ . μ₯ν λμλμ
Β·μ μλ°λν κ³νμ 98
μ 6μ₯ κ²°λ‘ 106
μ°Έκ³ λ¬Έν 108
Abstract 113Maste
Boundary behavior of harmonic functions for subordinate Brownian motion
νμλ
Όλ¬Έ (λ°μ¬)-- μμΈλνκ΅ λνμ : μ리과νλΆ, 2013. 2. κΉνκΈ°.In this thesis, we establish an oscillation estimate of nonnegative harmonic functions for a pure-jump subordinate Brownian motion. The infinitesimal generator of such subordinate Brownian motion is an integro-differential operator. As an application, we give a probabilistic proof of the following form of relative Fatou theorem for such subordinate Brownian motion in a bounded -fat open setif is a positive harmonic function with respect to in a bounded -fat open set and is a positive harmonic function in vanishing on , then the non-tangential limit of exists almost everywhere with respect to the Martin-representing measure of . Under the gaugeability assumption, relative Fatou theorem is true for operators obtained from the generator of pure-jump subordinate Brownian motion in bounded -fat open set through non-local Feynman-Kac transforms.1. Introduction
2. Preliminaries
2.1. Subordinate Brownian motion
2.2. Our hypothesis (A1) and its basic consequences
3. Oscillation of harmonic functions
3.1. Estimates on Levy density
3.2. Oscillation
4. Relative Fatou theorem
4.1. Hypothesis (A2) and its consequences
4.2. Martin kernel
4.3. Proof of the relative Fatou theorem
5. Relative Fatou theorem under non-local Feynman-Kac transforms
5.1. Non-local Feynman-Kac transforms
5.2. Stability of the relative Fatou theoremDocto
Precise Muscle Selection Using Dynamic Polyelectromyography for Treatment of Post-stroke Dystonia: A Case Report
Dystonia has a wide range of causes, but treatment of dystonia is limited to minimizing the symptoms as there is yet no successful treatment for its cause. One of the optimal treatment methods for dystonia is chemodenervation using botulinum toxin type A (BTX-A), alcohol injection, etc., but its success depends on how precisely the dystonic muscle is selected. Here, we reported a successful experience in a 49-year-old post-stroke female patient who showed paroxysmal repetitive contractions involving the right leg, which may be of dystonic nature. BTX-A and alcohol were injected into the muscles which were identified by dynamic polyelectromyography. After injection, the dystonic muscle spasm, cramping pain, and the range of motion of the affected lower limb improved markedly, and she was able to walk independently indoors. In such a case, dynamic polyelectromyography may be a useful method for selecting the dominant dystonic muscles.ope
The cholinergic contribution to the resting-state functional network in non-demented Parkinson's disease
The cholinergic system arising from the basal forebrain plays an important role in cognitive performance in Parkinson's disease (PD). Here, we analyzed cholinergic status-dependent cortical and subcortical resting-state functional connectivity in PD. A total of 61 drug-naive PD patients were divided into tertiles based on normalized substantia innominata (SI) volumes. We compared the resting-state network from seed region of interest in the caudate, posterior cingulate cortex (PCC), and SI between the lowest (PD-L) and highest tertile (PD-H) groups. Correlation analysis of the functional networks was also performed in all subjects. The functional network analysis showed that PD-L subjects displayed decreased striato-cortical functional connectivity compared with PD-H subjects. Selecting the PCC as a seed, the PD-L patients displayed decreased functional connectivity compared to PD-H patients. Meanwhile, PD-L subjects had significantly increased cortical functional connectivity with the SI compared with PD-H subjects. Correlation analysis revealed that SI volume had a positive correlation with functional connectivity from the right caudate and PCC. The present study demonstrated that PD patients exhibited unique functional connectivity from the caudate and the PCC that may be closely associated with cholinergic status, suggesting an important role for the cholinergic system in PD-associated cognition.ope
Familiar Hyperekplexia, a Potential Cause of Cautious Gait: A New Korean Case and a Systematic Review of Phenotypes
Familial hyperekplexia, also called startle disease, is a rare neurological disorder characterized by excessive startle responses to noise or touch. It can be associated with serious injury from frequent falls, apnea spells, and aspiration pneumonia. Familial hyperekplexia has a heterogeneous genetic background with several identified causative genes; it demonstrates both dominant and recessive inheritance in the Ξ±1 subunit of the glycine receptor (GLRA1), the Ξ² subunit of the glycine receptor and the presynaptic sodium and chloride-dependent glycine transporter 2 genes. Clonazepam is an effective medical treatment for hyperekplexia. Here, we report genetically confirmed familial hyperekplexia patients presenting early adult cautious gait. Additionally, we review clinical features, mode of inheritance, ethnicity and the types and locations of mutations of previously reported hyperekplexia cases with a GLRA1 gene mutation.ope
Factors Affecting Medication Adherence in Patients with Chronic Heart Failure
Purpose: The purpose of this study was to explore socio-demographic, clinical and psychological factors associated with medication adherence among patients with chronic heart failure (CHF). Methods: In a cross-sectional survey, 133 patients with CHF who had visited a clinic located in Seoul participated. Medication adherence (MA) was measured using a single item visual analogue rating scale (VAS). Barriers and attitudes toward adherence, and depression were measured using a structured questionnaire. Medical records were reviewed to identify their clinical characteristics. Multivariate logistic regression was performed identify factors affecting medication adherence. Results: About one third of participants (31.1%) reported their MA as 100%. Overall attitudes on MA were highly positive and 49 (36.8%) of participants were depressive. MA was associated with significantly barriers (p<.001), attitudes (p<.001), age (p<.001), and duration of disease (p<.001). The high adherent group had significantly less barriers than other groups (OR=.389, p=0.02). Conclusion: This study indicates that barriers and attitudes toward MA were the most important factors affecting their adherence to HF medication. To improve MA for patient with CHF, the nursing strategies which can lead poor adherent patients to their optimal level should be developed.ope
- β¦